ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma reported the completion of a US FDA inspection at its subsidiary, Lannett Company LLC, which resulted in four procedural observations.
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd., received a US FDA Warning Letter for its Unit I manufacturing facility. The unit contributes approximately 2% to group revenue.
Aurobindo Pharma has submitted its Business Responsibility & Sustainability Report for the financial year 2025-26 to the stock exchanges.
Aurobindo Pharma signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply generic alimatravir for 129 low- and middle-income countries.
US FDA completed an inspection at Auroactive Pharma, a wholly owned subsidiary. The inspection resulted in two observations to be responded to.
Aurobindo Pharma subsidiary's Unit-I facility received an 'official action indicated' (OAI) classification from the US FDA. The company maintains there is no financial impact.
Aurobindo Pharma's Unit-VII in Telangana received an Establishment Inspection Report (EIR) from the US FDA. The facility is classified as Voluntary Action Indicated (VAI), and the inspection is now closed. This follows a January-February 2026 inspection that initially resulted in nine observations.